<DOC>
	<DOCNO>NCT01640808</DOCNO>
	<brief_summary>The purpose study verify superiority NIK-333 ( Peretinoin ) placebo inhibit recurrence HCV-positive HCC patient show complete cure disease , recurrence-free survival primary endpoint , multi-center , randomize , double-blind , placebo-controlled , parallel-group comparison study .</brief_summary>
	<brief_title>Study Peretinoin Suppressing Recurrence HCV-positive HCC</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>1 . Patients HCVpositive HCC meet follow condition radical treatment Patients diagnose typical HCC dynamic CT , CTA/CTAP , dynamic MRI ( nodule visualize high signal intensity area arterial phase relatively low signal intensity area portal equilibrium phase ) perform within 8 week ( 56 day ) treatment start prior radical therapy Patients first primary HCC first recurrence primary HCC 2 . Patients receive radical therapy . The treatment duration ( start end treatment ) within 4 week ( 28 day ) radical therapy . 3 . Patients show complete cure , confirm dynamic CT image take 8 week ( 56 day ) 12 week ( 84 day ) end treatment show nonstained lowconcentration area overlap tumor image observe complete cure . 4 . Patients able begin treatment study drug within 8 week ( 56 day ) dynamic CT confirm complete cure 5 . Patients confirm satisfy follow condition base screen perform subject registration Positive serum hepatitis C virus nucleic acid ( HCVRNA ) Grade A ChildPugh classification Platelet count 50 000/ÂµL high 6 . Patients ECOG Performance Status score 0 1 7 . Patients age 20 year old time inform consent 1 . Patients positive HBs antigen 2 . Patients show vascular invasion HCC image diagnosis 3 . Patients also undergo transcatheter arterial embolization therapy ( TAE/TACE ) , transarterial infusion therapy ( TAI ) , chemolipiodolization combination radical therapy 4 . 4 Patients want receive antiviral therapy concomitant therapy intaferon study period 5 . Patients receive study drug , anticancer drug , interferon radical therapy 6 . Patients hypertension complication , whose blood pressure control drug therapy ( systolic blood pressure 160 mmHg high diastolic blood pressure 100 mmHg high , determine subject registration ) 7 . Patients history allergy CT contrast medium , whose participation study judge inappropriate investigator subinvestigator 8 . Patients history total gastrectomy 9 . Patients history cardiac arrest 10 . Patients follow laboratory value complication Creatinine &gt; = 1.5mg/dL Albumin urine &gt; = 1000mg/g Creatinine Cardiac disorder correspond CTCAE grade 3 severity HbA1c &gt; = 7.4 treatment insulin Autoimmune disease asthma treat oral steroid 11 . Patients confirm another malignant neoplasm undergone radical therapy HCC within past 5 year treat another malignant neoplasm ( however , apply endoscopic resection resection intraepithelial carcinoma ) 12 . Patients pregnant , possibility pregnant desire become pregnant study period 13 . Lactating woman 14 . Patients history allergy retinoidrelated substance ( vitamin A , etc . ) past 15 . Patients participate another clinical study within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>